The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Open accessAbstract
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2, who were germline BRCA1 and BRCA2 wild type 3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, the PARTNER trial reported no added benefit of olaparib when combined with neoadjuvant carboplatin/paclitaxel in BRCA-proficient TNBC, showing no improvement in pCR, event-free survival (EFS), or OS [58].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, neoadjuvant paclitaxel plus carboplatin achieved a pCR of 52% and a 36-month EFS of 79% in the PARTNER trial (NCT03150576) [58, 59].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888 · cited 1×
“The CREATE-X trial demonstrated a significant benefit in patients with TNBC from 6 months of adjuvant capecitabine given after neoadjuvant chemotherapy that left residual disease 25 .”
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Arun, B., Couch, F. J., Abraham, J., Tung, N., & Fasching, P. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02827-z · Cited by 94
“…did not improve pCR rates, event-free survival (EFS) or OS compared with paclitaxel and carboplatin alone among patients with non-gBRCAm and TNBC [46], improvements in EFS and OS were observed among patients with gBRCAm who received a gap schedule of olaparib with paclitaxel and carboplatin [45].”
BackgroundMethodSelf-citationHerencia-Ropero, A., Llop‐Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García‐Galea, E., Moles‐Fernández, A., Pedretti, F., Domènech, H., Rodríguez, O., Guzmán, M., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01370-z · Cited by 90
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Agelidis, A. M., Ter‐Zakarian, A., & Jaloudi, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516125 · Cited by 67
Basyuni, S., Heskin, L., Degasperi, A., Black, D., Koh, C. C., Chmelova, L., Rinaldi, G., Bell, S., Grybowicz, L., Elgar, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51577-2 · Cited by 48
Self-citation
Metadata
- Authors
- Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J. P., Sutherland, S., Staples, E., Scott, L. C., Davies, M., Palmer, C. A., Moody, M., Churn, M. J., Newby, J. C., Mukesh, M. B., Chakrabarti, A., Roylance, R. R., Schouten, P. C., Levitt, N. C., McAdam, K., Armstrong, A. C., Copson, E. R., McMurtry, E., Tischkowitz, M., Provenzano, E., & Earl, H. M.
- Affiliations
- University of Cambridge (GB)
- Athens University of Economics and Business (GR)
- Royal Devon University Healthcare NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Royal Bournemouth Hospital (GB)
- Russells Hall Hospital (GB)
- East Suffolk and North Essex NHS Foundation Trust (GB)
- University Hospitals of Derby and Burton NHS Foundation Trust (GB)
- Bedford Hospital NHS Trust (GB)
- Pinderfields Hospital (GB)
- Royal Hampshire County Hospital (GB)
- Velindre Cancer Centre (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- Mount Vernon Hospital (GB)
- Barking, Havering And Redbridge University Hospitals NHS Trust (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Swansea Bay University Health Board (GB)
- Hinchingbrooke Hospital (GB)
- West Suffolk NHS Foundation Trust (GB)
- Worcestershire Acute Hospitals NHS Trust (GB)
- Royal Free London NHS Foundation Trust (GB)
- Poole Hospital (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
- Peterborough City Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- University of Southampton (GB)
- Corresponding author
- Abraham, Jean E.
- ORCID
- Abraham, Jean E.
- Pinilla, Karen
- Dayimu, Alimu
- Grybowicz, Louise
- Lucey, Rebecca
- Fulton, Alexander
- Chhabra, Anita
- Qian, Wendi
- Hickish, Tamas
- Tripathi, Devashish
- Venkitaraman, Ramachandran
- Borley, Annabel
- Braybrooke, Jeremy P.
- Churn, Mark J.
- Chakrabarti, Amitabha
- Roylance, Rebecca R.
- Schouten, Philip C.
- McAdam, Karen
- Armstrong, Anne C.
- Copson, Ellen R.
- Tischkowitz, Marc
- Provenzano, Elena
- Earl, Helena M.
- Venue
- Nature
- Published
- 2024-04-08
- Volume
- 629
- Issue
- 8014
- Pages
- 1142-1148
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11136660
- OpenAlex
- W4394580299
- Cited by
- 53
- References
- 36
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 11
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, triple-negative breast cancer, neoadjuvant therapy, PARP inhibitors, carboplatin, paclitaxel, anthracycline chemotherapy, pathological complete response, event-free survival, overall survival
- MeSH terms
- Progression-Free Survival, Pathologic Complete Response, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Phthalazines, Piperazines, Prospective Studies, Time Factors, Survival Analysis, Carboplatin, Paclitaxel, Germ-Line Mutation, Anthracyclines, BRCA1 Protein, Genes, BRCA1, Neoadjuvant Therapy, Genes, BRCA2, BRCA2 Protein, Young Adult, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. https://app.cochat.ai/papers/10.1038/s41586-024-07384-2
- The paper
- Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., . . . Earl, H. M. (2024). The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. https://doi.org/10.1038/s41586-024-07384-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.